Protective effect of captopril, olmesartan, melatonin and compound 21 on doxorubicin-induced nephrotoxicity in rats
Language English Country Czech Republic Media print
Document type Comparative Study, Journal Article, Research Support, Non-U.S. Gov't
PubMed
24329698
DOI
10.33549/physiolres.932614
PII: 932614
Knihovny.cz E-resources
- MeSH
- Antioxidants therapeutic use MeSH
- Angiotensin II Type 1 Receptor Blockers therapeutic use MeSH
- Renal Insufficiency, Chronic chemically induced drug therapy physiopathology MeSH
- Doxorubicin MeSH
- Glomerular Filtration Rate drug effects MeSH
- Imidazoles therapeutic use MeSH
- Angiotensin-Converting Enzyme Inhibitors therapeutic use MeSH
- Captopril therapeutic use MeSH
- Rats MeSH
- Renal Agents therapeutic use MeSH
- Melatonin therapeutic use MeSH
- Oxidative Stress drug effects MeSH
- Rats, Wistar MeSH
- Reactive Oxygen Species metabolism MeSH
- Receptor, Angiotensin, Type 2 agonists MeSH
- Tetrazoles therapeutic use MeSH
- Treatment Outcome MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Male MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Comparative Study MeSH
- Names of Substances
- Antioxidants MeSH
- Angiotensin II Type 1 Receptor Blockers MeSH
- Doxorubicin MeSH
- Imidazoles MeSH
- Angiotensin-Converting Enzyme Inhibitors MeSH
- Captopril MeSH
- Renal Agents MeSH
- Melatonin MeSH
- olmesartan MeSH Browser
- Reactive Oxygen Species MeSH
- Receptor, Angiotensin, Type 2 MeSH
- Tetrazoles MeSH
Chronic kidney disease (CKD) represents a serious public health problem with increasing prevalence and novel approaches to renal protection are continuously under investigation. The aim of this study was to compare the effect of melatonin and angiotensin II type 2 receptor agonist compound 21 (C21) to angiotensin converting enzyme inhibitor captopril and angiotensin II type 1 receptor blocker olmesartan on animal model of doxorubicin nephrotoxicity. Six groups of 3-month-old male Wistar rats (12 per group) were treated for four weeks. The first group served as a control. The remaining groups were injected with a single dose of doxorubicin (5 mg/kg i.v.) at the same day as administration of either vehicle or captopril (100 mg/kg/day) or olmesartan (10 mg/kg/day) or melatonin (10 mg/kg/day) or C21 (0.3 mg/kg/day) was initiated. After four week treatment, the blood pressure and the level of oxidative stress were enhanced along with reduced glomerular density and increased glomerular size. Captopril, olmesartan and melatonin prevented the doxorubicin-induced increase in systolic blood pressure. All four substances significantly diminished the level of oxidative burden and prevented the reduction of glomerular density and modestly prevented the increase of glomerular size. We conclude that captopril, olmesartan, melatonin and C21 exerted a similar level of renoprotective effects in doxorubicin-induced nephrotoxicity.
References provided by Crossref.org
Lactacystin-induced kidney fibrosis: Protection by melatonin and captopril
Ivabradine Ameliorates Kidney Fibrosis in L-NAME-Induced Hypertension